RESEARCH TRIANGLE PARK, N.C. – June 4, 2012 – To help biopharmaceutical and government organizations better understand how medicines are used and perform in “real world” settings, Quintiles today announced recent signings and commitments to multiple sources of data that will give it access to de-identified electronic medical records (EMR) data representing 40 million patient lives.
When these licensing agreements take effect, Quintiles will have significantly expanded the amount of HIPAA-compliant EMR data its researchers can use to help healthcare stakeholders better understand real-world treatments and outcomes, and for clinical trial planning to enhance drug development efficiency.
The EMR data are primarily from U.S.-based medical practices and health systems; it is anticipated that such data from other countries will be added in the future. The data reflect a representative sample of the healthcare experiences and detailed clinical treatment of patients across all therapeutic categories and from a wide variety of U.S. healthcare settings.
“Biopharma and governmental organizations need more clinically rich data to better evaluate the safety, effectiveness and value of healthcare products and services in actual clinical practice,” said Richard Gliklich, M.D., President, Quintiles Outcome, the real-world and late phase division of Quintiles. “These recent agreements, and our plans to add research experts who have worked with these data over many years, provide Quintiles with a critical mass of high-quality and clinically rich patient-level data to find answers to research questions more rapidly.
“I believe access to these data by experienced researchers also will promote more efficient clinical trial planning and design, patient recruitment, and other clinical development services.”
Quintiles is in the process of adding a research and analysis team that is expert in the use of the new EMR data for both prospective and retrospective observational research. These experts will provide customers insights useful in outcomes research; health economics; epidemiology; medical informatics; quality reporting; and pricing and reimbursement, among other uses.
Quintiles’ vision is to use data and analytics to provide its customers with knowledge-based services and solutions that dramatically improve efficiency, productivity and quality across the spectrum from clinical development to healthcare delivery.
Quintiles is the only fully integrated biopharmaceutical services company offering clinical, commercial, consulting and capital solutions worldwide. Our network of more than 25,000 professionals in 60 countries has an eye on the future while delivering results today with an unwavering commitment to patients, safety and ethics. Quintiles helps biopharmaceutical companies develop and commercialize products to improve and lengthen patients’ lives while demonstrating value to stakeholders. Visit www.quintiles.com for more information and www.quintiles.com/news for additional company news.